Gynecologic Cancer News and Features

Indices for early symptoms of ovarian cancer may need tweaking

January 27, 2012

The clinical utility of a symptom index for ovarian cancer depends on precisely how it is used and how index-positive women are managed, indicate the results of a recent study.
 

Bevacizumab delays return of ovarian cancer

Delicia Honen Yard January 13, 2012

The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
 

Genetic variation in ovarian cancer thwarts treatment

Delicia Honen Yard December 27, 2011

Women with a variant of the KRAS oncogene are three times more resistant to platinum chemotherapy, the standard treatment for ovarian cancer, than are women without this variant.
 

Diabetes drug helps prevent growth of breast cancer cells

Delicia Honen Yard December 09, 2011

Metformin, a widely used agent in the treatment of type 2 diabetes, stopped a number of natural and man-made chemicals from stimulating the growth of breast cancer cells.
 

Self-testing for HPV may increase screening rates

Delicia Honen Yard November 17, 2011

Vaginal self-sampling for human papillomavirus testing demonstrated a relatively low but acceptable positive predictive value in a large trial of women in underserved areas of Mexico.
 

Endometrial cancer risk increases with adult weight gain but not with yo-yo dieting

Delicia Honen Yard November 16, 2011

Postmenopausal women who have gained weight in adulthood are at greater risk of developing endometrial cancer than are women who maintain a stable weight, indicates a recent study.
 

Fluorescence-guided surgery puts ovarian cancer in a new light

Delicia Honen Yard October 19, 2011

A surgical method employing fluorescent imaging agents can help surgeons remove malignant tissue that otherwise might have been missed in women with ovarian cancer.
 

Oxygen generators help kill tumors from within

October 18, 2011

An electronic device that can be implanted in a tumor uses the energy from ultrasound signals to generate oxygen, boosting the effectiveness of radiation and chemotherapy.
 

PARP inhibitor found effective in women without BRCA mutation

October 18, 2011

A poly(ADP-ribose) polymerase (PARP) inhibitor that has shown promising anticancer activity in the presence of BRCA1 or BRCA2 gene mutations also appears to be effective in the treatment of more common, nonhereditary ovarian tumors.
 

Costly clots common in cancer

Delicia Honen Yard October 18, 2011

As many as 1 in 5 people risk developing a venous thromboembolism (VTE) within a year after undergoing treatment for some types of cancers, researchers reported.
 

Gynecologic Cancer Clinical Trials

Clinical Trial: Female Cancer Patients' Preference For Sexual Health Interventions

Clinical Trial: Ultrasound Hyperthermia Therapy After Implant Radiation Therapy in Treating Patients With Urinary Tract Cancer, Gynecologic Cancer, or Head and Neck Cancer

Clinical Trial: Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers

Clinical Trial: Pelvic Exenteration for Gynecologic Malignancy

Clinical Trial: Assessment of Screening Modalities for Gynecologic Cancers

 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions